Aviva’s Akero Therapeutics AKRO Stock Holding History

Aviva’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-39,880	Closed	-$1.16M	–	864
2021 Q1	$1.16M	Buy	+39,880	New	+$1.21M	0.01%	887

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

YCM

Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Aviva's AKRO Position: Q2 2021 in Review

Aviva sold out of Akero Therapeutics (AKRO) in Q2 2021, closing a stake of 39,880 shares — an estimated $1.16M sold.

Aviva first reported a position in AKRO in Q1 2021 and held it in 1 quarter. The position peaked at $1.16M in Q1 2021. 97 funds tracked by Wall St. Rank hold AKRO as of Q2 2021.

Aviva reported no remaining Akero Therapeutics position as of Q2 2021 after selling out during the quarter.
Aviva sold 39,880 Akero Therapeutics shares in Q2 2021, an estimated $1.16M.
Aviva first reported a position in Akero Therapeutics in Q1 2021 and held it in 1 quarter.
Aviva's Akero Therapeutics position peaked at $1.16M in Q1 2021.
97 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2021.

Based on Aviva's 13F filing for Q2 2021, filed 10 Aug 2021.